Agomab Therapeutics (AGMB) CMO lists vested stock option grants
Rhea-AI Filing Summary
Agomab Therapeutics NV Chief Medical Officer Philippe Constantin Wiesel reported his initial holdings of stock options on the company’s common shares. The filing lists ten option grants with exercise prices between $0.0005 and $14.26, expiring from 2029 through 2036. Footnotes explain which grants are already fully vested and which vest over time, and note that each American Depositary Share currently represents one common share.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Wiesel Philippe Constantin
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 627,775 shares (Direct)
Footnotes (5)
- F1. The shares underlying this option are fully vested and exercisable.
- F2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
- F3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
- F4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F5. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Philippe Constantin Wiesel report in his Agomab (AGMB) Form 3?
Philippe Constantin Wiesel reports his initial holdings of stock options on Agomab Therapeutics common shares. The Form 3 lists ten direct option grants, detailing exercise prices, expiration dates, and vesting status as his baseline derivative position as Chief Medical Officer.
What stock option exercise prices are disclosed for the Agomab (AGMB) CMO?
The filing shows stock option exercise prices on Agomab common shares ranging from $0.0005 to $14.26. These prices are reported in U.S. dollars after converting from euros at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
How do the Agomab (AGMB) CMO’s option grants vest according to the Form 3?
Some options are fully vested and exercisable, while others follow schedules. One grant vested 50% on February 9, 2026, with the rest vesting in 24 equal monthly installments. Another vests 25% on February 9, 2027, with the balance vesting in 36 monthly installments.
What are the expiration dates of the Agomab (AGMB) CMO’s reported stock options?
The Chief Medical Officer’s stock options on Agomab common shares carry expiration dates between 2029 and 2036. Individual grants expire on specific dates such as March 14, 2029, October 9, 2029, and January 15, 2036, defining the periods during which they can be exercised.